Estándar de tratamiento en primera línea de cáncer de páncreas metastásico: ¿ABRAXANE-GEMCITABINA o FOLFIRINOX? - page 10

Tabernero et al. Beaujon Conference 2014

Pacientes ECOG 0-1 MPACT

Mediana de SG: 9,7 meses

Tabernero J et al, The Oncologist 2015;20:1–8

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1,2,3,4,5,6,7,8,9 11,12,13,14,15,16,17,18,19,20,...22